Paraplatin

(Carboplatin)

ApprovedSmall molecule

Carboplatin is a chemotherapy drug used to treat various cancers, including ovarian cancer, lung cancer, and others. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Paraplatin is currently approved and in use across 238 indications[4].[1]

Paraplatin is one of 2021 small molecule programs targeting Glioma. It is currently in Approved.

238

Indications

2,335

Total Trials

Active Trials

2,020

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

EpendymomaActive, not recruiting

Peritoneum CancerApproved

SeminomaActive, not recruiting

HIV InfectionActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Non-Hodgkins LymphomaApproved

Merkel Cell Skin CancerApproved

GliomaPhase 3

Active, not recruiting

Head and Neck CarcinomaPhase 2

Active, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

EpendymomaPhase 3

Active, not recruiting

Peritoneum CancerApproved

Approved

SeminomaPhase 3

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2/Phase 3

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

Merkel Cell Skin CancerApproved

Approved

Showing 10 of 237 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Paraplatin

Halaven

38 3

MS Contin

Merck & Co.

Preclinical

2 4

Lexiscan

Astellas

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Tricor

JJagotec

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Acupan

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Pembrolizumab

NCT04652076

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT04253964

Phase 3Active, not recruiting

Neuroblastoma

NCT02176967

Q4 2026

Phase 2Active, not recruiting

Oropharyngeal Carcinoma

NCT03323463

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT05990127

Phase 2Active, not recruiting

Non-Squamous NSCLC

NCT04163432

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer33 trials

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04253964·105 enrolled

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT02492867·49 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

Show 30 more trials

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Terminated· Roche logo

Roche·Phase 2·NCT00434226·56 enrolled

Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Unknown status·HHope Cancer Institute, Inc.·Phase 2·NCT00003562·38 enrolled

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04379635·453 enrolled

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06692738·880 enrolled

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting·AAkeso·Phase 3·NCT05990127·642 enrolled

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00547443

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01413750·23 enrolled

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03574649

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00469976

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Completed·UUniversity of Miami·N/A·NCT01209520·6 enrolled

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003117·584 enrolled

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT03871153·7 enrolled

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003313·243 enrolled

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00828009·70 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00350792·62 enrolled

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Terminated·MMilton S. Hershey Medical Center·Phase 1·NCT00714246·6 enrolled

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00041314

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00563784·68 enrolled

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 2·NCT01507428·138 enrolled

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00369551·36 enrolled

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 1·NCT01723800·9 enrolled

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

Terminated·WWest Virginia University·Phase 1·NCT02252796·1 enrolled

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05984277·1,200 enrolled

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Completed·EECOG-ACRIN Cancer Research Group··NCT00900172·180 enrolled

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05487391·632 enrolled

Breast Cancer17 trials

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT01167192·10 enrolled

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00616967·68 enrolled

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Terminated·PPamela Munster·Phase 1·NCT02358200·23 enrolled

Show 14 more trials

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03554044·20 enrolled

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05177796

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01036087·47 enrolled

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04191135·462 enrolled

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005963·53 enrolled

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Recruiting·NNorthwestern University·Phase 2·NCT03213041·100 enrolled

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Completed·—·Phase 2·NCT02789657·32 enrolled

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00446030·127 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06797635·372 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981001·170 enrolled

Small Cell Lung Cancer10 trials

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04951115·6 enrolled

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00042978·55 enrolled

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03043872·987 enrolled

Show 7 more trials

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00695292·37 enrolled

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Completed·SShadia Jalal, MD·Phase 2·NCT03913455·24 enrolled

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02279732·342 enrolled

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00041054·41 enrolled

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00927875·5 enrolled

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03059667·73 enrolled

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00469898·50 enrolled

Ovarian Cancer9 trials

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Terminated·MMersana Therapeutics·Phase 1·NCT04907968·31 enrolled

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00660842·800 enrolled

Show 6 more trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT06840002·150 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00003136·11 enrolled

A Study LY2228820 for Recurrent Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01663857·118 enrolled

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Completed· Roche logo

Roche··NCT02393898·76 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Cervical Cancer6 trials

Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

Active, not recruiting·UUniversity College, London·Phase 3·NCT01566240·500 enrolled

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT03534713·310 enrolled

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Not yet recruiting·GGuangzhou Gloria Biosciences Co., Ltd.·Phase 3·NCT05798819·424 enrolled

Show 3 more trials

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04974944·172 enrolled

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT04238988·45 enrolled

Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer

Terminated·—·Phase 3·NCT01461772·21 enrolled

75 more indications

Lung Cancer6 trials

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

Completed·BBioNTech US Inc.·Phase 1·NCT03380871·38 enrolled

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Terminated·WWuhan University·Phase 2·NCT03802058·24 enrolled

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Unknown status·FFudan University·Phase 2·NCT04592666·226 enrolled

Show 3 more trials

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Unknown status·—·Phase 2·NCT00150657·45 enrolled

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00147537·282 enrolled

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087241·22 enrolled

Chemotherapy5 trials

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT00499109·275 enrolled

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting·NNew York Medical College·Phase 2·NCT02393157·25 enrolled

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00529503·151 enrolled

Show 2 more trials

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Completed·CChildren's Oncology Group·Phase 3·NCT00002944·428 enrolled

Germ Cell Tumor5 trials

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Unknown status·OOHSU Knight Cancer Institute·Phase 1/2·NCT00983398·17 enrolled

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02161692

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423852·26 enrolled

Show 2 more trials

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Recruiting·BBeihua Kong·Phase 3·NCT02429687·129 enrolled

Neuroblastoma5 trials

A Study of N9 Chemotherapy in Children With Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00287950·120 enrolled

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Show 2 more trials

Combination Chemotherapy in Treating Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003093·573 enrolled

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02176967·621 enrolled

Advanced Solid Tumors4 trials

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Withdrawn· Incyte logo

Incyte·Phase 1·NCT03920839

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00648648·206 enrolled

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

Show 1 more trial

A Study in Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01063075·34 enrolled

Patients With Advanced Solid Tumors4 trials

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

Terminated·MMatthew Galsky·Phase 1·NCT01496534·14 enrolled

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Completed·MMerrimack Pharmaceuticals·Phase 1·NCT01447225·43 enrolled

Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors

Completed·UUniversity of Pittsburgh·Phase 1·NCT00008086

Show 1 more trial

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Terminated·SSyros Pharmaceuticals·Phase 1·NCT03134638·107 enrolled

Immunotherapy4 trials

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Suspended·UUniversity of Maryland, Baltimore·Phase 1·NCT05403723·50 enrolled

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Terminated·—·Phase 2·NCT04923776·2 enrolled

Show 1 more trial

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

Active, not recruiting·FFundación GECP·Phase 3·NCT04564157·210 enrolled

Fallopian Tube Cancer4 trials

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Terminated·CCraig L Slingluff, Jr·Phase 2·NCT00373217·6 enrolled

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191646·919 enrolled

Show 1 more trial

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00951496·1,560 enrolled

Carboplatin3 trials

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Terminated·SSeattle Institute for Biomedical and Clinical Research·Phase 2·NCT02985021·2 enrolled

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Not yet recruiting·RRenJi Hospital·Phase 2·NCT07283692·46 enrolled

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01237067·77 enrolled

Non-squamous NSCLC3 trials

Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Active, not recruiting·UUniversity of Utah·Phase 2·NCT04163432·43 enrolled

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04686305·244 enrolled

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Unknown status·SShanghai Chest Hospital·Phase 2·NCT04405674·120 enrolled

Lymphoma3 trials

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00255723·98 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02703272·72 enrolled

Triple-Negative Breast Cancer3 trials

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Completed·—·Phase 2·NCT03121352·30 enrolled

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03499899·88 enrolled

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06279364·524 enrolled

Bladder Cancer3 trials

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Completed·AAchieve Life Sciences·Phase 2·NCT01454089·183 enrolled

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01916109·4 enrolled

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated·SStanford University·Phase 2·NCT03912818·7 enrolled

Endometrial Cancer3 trials

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00470067·9 enrolled

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Unknown status·GGynecologic Oncology Group·Phase 2/3·NCT02065687·469 enrolled

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Completed·GGOG Foundation·Phase 3·NCT00063999·1,381 enrolled

Urothelial Cancer2 trials

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Completed·UUniversity Health Network, Toronto·Phase 2·NCT03520231·6 enrolled

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05911295·412 enrolled

Glioblastoma Multiforme2 trials

Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme

Completed·NNYU Langone Health·Phase 2·NCT00010036

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

Completed·NNYU Langone Health·Phase 2·NCT00002619·60 enrolled

Esophageal Cancer2 trials

Chemoradiation and Panitumumab for Esophageal Cancer

Completed·—·Phase 2·NCT01077999·78 enrolled

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Terminated·SStanford University·Phase 1·NCT00368329·4 enrolled

Neoadjuvant Chemotherapy2 trials

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Completed·RRitu Salani·Phase 1·NCT01219777·9 enrolled

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Not yet recruiting·SShanghai Chest Hospital·Phase 2·NCT06688656·30 enrolled

Stage IV Ovarian Epithelial Cancer2 trials

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Completed·AAGO Study Group·Phase 3·NCT00006454

Nasopharyngeal Carcinoma2 trials

Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT02250599·80 enrolled

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

Completed·SStanford University·Phase 2·NCT00896181·26 enrolled

Pembrolizumab2 trials

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting·NNETRIS Pharma·Phase 1/2·NCT04652076·240 enrolled

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1/2·NCT05083481·366 enrolled

Primary Peritoneal Cancer2 trials

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNRG Oncology·Phase 3·NCT04095364·450 enrolled

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00005026

Squamous Cell Carcinoma2 trials

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07121595·50 enrolled

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Completed·OOncolytics Biotech·Phase 2·NCT00998192·32 enrolled

Neoadjuvant Therapy1 trial

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT04877821·31 enrolled

Recurrent or Metastatic1 trial

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02124707·14 enrolled

Ependymoma1 trial

Carboplatin and Bevacizumab for Recurrent Ependymoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01295944·35 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04568200·60 enrolled

Gynecologic Cancer1 trial

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT01281514·21 enrolled

First-line Treatment1 trial

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Recruiting·PPeking University Cancer Hospital & Institute·Phase 1·NCT06969612·21 enrolled

Locally Advanced1 trial

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Recruiting·TTang-Du Hospital·Phase 2·NCT07353723·10 enrolled

Ovarian Epithelial Cancer1 trial

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

Advanced Solid Cancer1 trial

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00535119·107 enrolled

Thoracic Tumors1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Recruiting· Amgen logo

Amgen·Phase 1·NCT06333951·500 enrolled

Solid Tumours1 trial

Phase I Study in Patients With Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00496028·148 enrolled

Cisplatin1 trial

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Completed·WWomen's Cancer Care Associates, LLC·Phase 3·NCT02501954·48 enrolled

Advanced or Metastatic Solid Tumors1 trial

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00793897·21 enrolled

Esophageal Adenocarcinoma1 trial

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Unknown status·—·Phase 2·NCT02037048·63 enrolled

Carcinosarcoma1 trial

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Completed·UUniversity of Oklahoma·Phase 1·NCT03206177·26 enrolled

Nab-paclitaxel1 trial

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04015778·48 enrolled

PARP Inhibitor1 trial

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00516724·189 enrolled

Advanced NSCLC1 trial

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Active, not recruiting·LLi Zhang, MD·Phase 3·NCT04695925·294 enrolled

Advanced Cancer1 trial

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003376·330 enrolled

Refractory Solid Tumors1 trial

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01478685·169 enrolled

Ovarian Tumor1 trial

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01357161·136 enrolled

Kidney Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Endometrial Carcinoma1 trial

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Completed·NNational Cancer Institute, Naples·Phase 2·NCT00401635·42 enrolled

Patients With Solid Tumors1 trial

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01301716·75 enrolled

Cancer of Unknown Primary1 trial

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Unknown status·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00003558·140 enrolled

Gastroesophageal Junction Cancer1 trial

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Completed·AApexigen America, Inc.·Phase 2·NCT03165994·34 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

NSCLC1 trial

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

Withdrawn·VVirginia Commonwealth University·Phase 1·NCT02059967

Radiation Therapy1 trial

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Melanoma1 trial

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00976573·149 enrolled

Fluorouracil1 trial

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00707473·31 enrolled

Solid Tumors1 trial

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01617928·12 enrolled

Neoadjuvant Treatment1 trial

Pathological Response After Neoadjuvant Treatment on NSCLC

Recruiting·FFundación GECP··NCT05167487·150 enrolled

Prostate Cancer1 trial

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Suspended·MM.D. Anderson Cancer Center·Phase 1/2·NCT06085729·30 enrolled

Brain Tumors1 trial

Lobradimil and Carboplatin in Treating Children With Brain Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019422

Metastatic1 trial

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01009346·9 enrolled

Malignant Brain Tumors1 trial

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Completed· Incyte logo

Incyte·Phase 3·NCT03358472·89 enrolled

Metastatic Urothelial Cancer1 trial

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT04223856·886 enrolled

Pleural Mesothelioma1 trial

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05136677·102 enrolled

Ovarian1 trial

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Recruiting·BBeihua Kong·Phase 3·NCT02429700·132 enrolled

Oropharyngeal Cancer1 trial

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

Completed·UUniversity of Chicago·Phase 1·NCT04572100·50 enrolled

Primary Peritoneal Cavity Cancer1 trial

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·—·Phase 2/3·NCT00075712·150 enrolled

Oropharyngeal Carcinoma1 trial

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03323463·316 enrolled

CDK4/6 Inhibitor1 trial

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Completed·GG1 Therapeutics, Inc.·Phase 2·NCT03041311·107 enrolled

Advanced Urothelial Cancer1 trial

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00151034·33 enrolled

Head and Neck Cancer1 trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT07065630·38 enrolled

Oral Squamous Cell Carcinoma1 trial

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Unknown status·XXin-Hua Xu·Phase 2·NCT04367909·68 enrolled

Adjuvant Treatment1 trial

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04455594·168 enrolled

Chemoradiotherapy1 trial

Chemoradiotherapy in Elderly Patients With Oesophagus Cancer

Recruiting·—·Phase 1/2·NCT02735057·54 enrolled

Central Nervous System Lymphoma1 trial

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Unknown status·OOHSU Knight Cancer Institute·Phase 1/2·NCT00293475·81 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 3, 1989

PARAPLATIN

NDA NDA019880

Jul 14, 2003

PARAPLATIN

NDA NDA020452

Aug 8, 2025

KYXATA

NDA NDA219921

Sources

References

[1]
ClinicalTrials.gov — 2335 trial records for Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Paraplatin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219921). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Paraplatin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Avyxa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAvyxa

Patent Landscape[6]

Patent Cliff

Apr 1, 2045

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12427104Apr 1, 2045